Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 23, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
SARS-CoV 2
Interventions
BIOLOGICAL

Hyperimmune plasma

PLASMA OF CONVALESCENT COVID-19

DRUG

Standard of care for SARS-CoV-2 infection

Standard of care for SARS-CoV-2 infection

Trial Locations (14)

11009

Hospital U. Puerta del Mar, Cadiz

11407

Hospital U. Jerez de la Frontera, Jerez de la Frontera

11510

Hospital U. Puerto Real, Puerto Real

18014

Hospital U. Virgen de las Nieves, Granada

18016

Hospital U. San Cecilio, Granada

21005

Hospital Juan Ramón Jiménez, Huelva

29010

Hospital Regional U. de Málaga, Málaga

Hospital U. Virgen de la Victoria, Málaga

29603

Hospital Costa del Sol, Marbella

41009

Hospital Unversitario Virgen Macarena, Seville

41013

Hospital Universitario Virgen del Rocío, Seville

41014

Hospital U. Nuestra Señora de Valme, Seville

41930

Hospital San Juan de Dios, Seville

04009

Hospital U. Torrecárdenas, Almería

All Listed Sponsors
lead

Andalusian Network for Design and Translation of Advanced Therapies

OTHER

NCT04366245 - Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection | Biotech Hunter | Biotech Hunter